Abstract
Melanoma is the malignant tumor of melanocytes. The most common type is cutaneous melanoma on what we will focus. The demonstration of early spread of melanoma cells in animal models and the detection of circulating melanoma cells in patients with thin tumors argue against the dogma of metastasis as a late tumor event. On the other hand, late (≥10 years) recurrence has been observed in up to 3.5% of patients. The paradoxon of early spread and late metastasis argues for melanoma cell dormancy. Because late recurrence is not related to increased tumor thickness but may occur in tumors thinner than 0.5 mm, a life-long follow-up for all melanoma patients seems mandatory. Improved patient education in skin self-examination and easy availability of outpatient dermatology service are the most important tools.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF (2004) An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54:131–149
Barkan D, Chambers AF (2011) β1-Integrin: a potential therapeutic target in the battle against cancer recurrence. Clin Cancer Res 17:7219–7223
Brauer JA, Wriston CC, Troxel AB, Elenitsas R, Shin DB, Guerry D, Ming ME (2010) Characteristics associated with early and late melanoma metastases. Cancer 116:415–423
Crowley NJ, Seigler HF (1990) Late recurrence of malignant melanoma: analysis of 168 patients. Ann Surg 212:173–177
De Giorgi V, Pinzani P, Salvianti F, Panelos J, Paglierani M, Janowska A, Grazzini M, Wechsler J, Orlando C, Santucci M, Lotti T, Pazzagli M, Massi D (2010) Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma. J Invest Dermatol 130:2440–2447
Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G, ESMO Guidelines Working Group (2010) Melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 5:194–197
Eyles J, Puaux AL, Wang X, Toh B, Prakash C, Hong M, Tan TG, Zheng L, Ong LC, Jin Y, Kato M, Prévost-Blondel A, Chow P, Yang H, Abastado JP (2010) Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma. J Clin Invest 120:2030–2039
Garbe C, Leiter U (2009) Melanoma epidemiology and trends. Clin Dermatol 27:3–9
Garbe C, Schadendorf D, Stolz W, Volkenandt M, Reinhold U, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R, Hauschild A (2008) Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 6(1):9–14
Hadfield G (1954) The dormant cancer cell. Br Med J 2:607–610
Hansel G, Schönlebe J, Haroske G, Wollina U (2010) Late recurrence (10 years or more) of malignant melanoma in south-east Germany (Saxony). Single-centre analysis of 1881 patients with a follow-up of 10 years or more. J Eur Acad Dermatol Venereol 24:833–836
Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, Stierner U, von der Maase H, Nordic Melanoma Cooperative Group (2011) Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. Lancet Oncol 13:144–152
Hohnheiser AM, Gefeller O, Göhl J, Schuler G, Hohenberger W, Merkel S (2011) Malignant melanoma of the skin: long-term follow-up and time to first recurrence. World J Surg 35:580–589
Hull PR, Piemontesi NG, Lichtenwald J (2011) Compliance with self-examination surveillance in patients with melanoma and atypical moles: an anonymous questionnaire study. J Cutan Med Surg 15:97–102
Ireland A, Millward M, Pearce R, Lee M, Ziman M (2011) Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management. Clin Exp Metastasis 28:327–336
Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7–17
Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, Breuninger H, Garbe C (2008) Age and gender are significant independent predictors of survival in primary malignant cutaneous melanoma. Cancer 112:1795–1804
Leiter U, Buettner PG, Eigentler TK, Bröcker EB, Voit C, Gollnick H, Marsch W, Wollina U, Meier F, Garbe C (2012) Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry. J Am Acad Dermatol 66:37–45
Leman JA, Mac Kie RM (2003) Late (>10 years) recurrence of melanoma: the Scottish experience. Br J Dermatol 148:372–373
Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, Gore ME, Lorigan P, Mackie R, Nathan P, Peach H, Powell B, Walker C, British Association of Dermatologists (BAD) Clinical Standards Unit (2010) Revised UK guidelines for the management of cutaneous melanoma. J Plast Reconstr Aesthet Surg 63:1401–1419
Ossowski L, Aguirre-Ghiso JA (2010) Dormancy of metastatic melanoma. Pigment Cell Melanoma Res 23:41–56
Panigrahy D, Edin ML, Lee CR, Huang S, Bielenberg DR, Butterfield CE, Barnés CM, Mammoto A, Mammoto T, Luria A, Benny O, Chaponis DM, Dudley AC, Greene ER, Vergilio JA, Pietramaggiori G, Scherer-Pietramaggiori SS, Short SM, Seth M, Lih FB, Tomer KB, Yang J, Schwendener RA, Hammock BD, Falck JR, Manthati VL, Ingber DE, Kaipainen A, D’Amore PA, Kieran MW, Zeldin DC (2012) Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice. J Clin Invest 22:78–79
Peters A, Lippold A, Hundeiker M (1997) First metastasis of malignant melanoma 10 or more years after treatment. Hautarzt 48:311–317
Schmid-Wendtner MH, Baumert J, Schmidt M, Konz B, Hölzel D, Plewig G, Volkenandt M (2000) Late metastases of cutaneous melanoma: an analysis of 31 patients. J Am Acad Dermatol 43:605–609
Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111
Shaw HM, Beattie CW, McCarthy WH, Milton GW (1985) Late relapse from cutaneous stage I malignant melanoma. Arch Surg 120:1155–1159
Shih ST, Carter R, Sinclair C, Mihalopoulos C, Vos T (2009) Economic evaluation of skin cancer prevention in Australia. Prev Med 49:449–453
Tsao H, Cosimi AB, Sober AJ (1997) Ultra-late recurrence (15 years or longer) of cutaneous melanoma. Cancer 79:2361–2370
Turner RM, Bell KJ, Morton RL, Hayen A, Francken AB, Howard K, Armstrong B, Thompson JF, Irwig L (2011) Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanoma. J Clin Oncol 29:4641–4646
Uliasz A, Lebwohl M (2007) Patient education and regular surveillance results in earlier diagnosis of second primary melanoma. Int J Dermatol 46:575–577
Wolff J, Wollina U (2000) Second malignancies in melanoma patients in Thuringia. J Eur Acad Dermatol Venereol 14:479–483
Xu X, Zhang XA, Wang DW (2011) The roles of CYP450 epoxygenases and metabolites, epoxyeicosatrienoic acids, in cardiovascular and malignant diseases. Adv Drug Deliv Rev 63:597–609
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Wollina, U. (2013). Late Recurrence Is a Sign of Melanoma Dormancy: Need of Life-Long Follow-Up of Melanoma Patients. In: Hayat, M. (eds) Tumor Dormancy, Quiescence, and Senescence, Volume 1. Tumor Dormancy and Cellular Quiescence and Senescence, vol 1. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-5958-9_7
Download citation
DOI: https://doi.org/10.1007/978-94-007-5958-9_7
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-5957-2
Online ISBN: 978-94-007-5958-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)